Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Outstanding (Weighted Average) (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $55.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 19.59% year-over-year to $55.3 million, compared with a TTM value of $55.3 million through Dec 2025, up 19.59%, and an annual FY2025 reading of $55.3 million, up 19.59% over the prior year.
  • Shares Outstanding (Weighted Average) was $55.3 million for Q4 2025 at Zevra Therapeutics, up from $54.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $55.3 million in Q4 2025 and bottomed at $19.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $39.1 million, with a median of $35.0 million recorded in 2021.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 647.71% in 2021, while the deepest fall reached 60.17% in 2021.
  • Year by year, Shares Outstanding (Weighted Average) stood at $29.8 million in 2021, then grew by 15.87% to $34.5 million in 2022, then grew by 2.79% to $35.5 million in 2023, then soared by 30.46% to $46.3 million in 2024, then rose by 19.59% to $55.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ZVRA at $55.3 million in Q4 2025, $54.9 million in Q3 2025, and $54.8 million in Q2 2025.